Prescription medicine
Lofexidine Brand names: Lucemyra
Lofexidine (Lucemyra) is a prescription medicine with an FDA approval on record since 2018. FDA's NDC Directory lists it from 4 generic labelers, and pharmacies paid $7.88 per lofexidine 0.18 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the lofexidine FDA label on DailyMed (effective July 22, 2026, BioCorRx Pharmaceuticals Inc); the NDA 209229 record on Drugs@FDA; every lofexidine label on DailyMed.
Highlights of the record
FDA label of July 22, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageLUCEMYRA is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Forms and strengths
- 0.18 mg
- 0.2 mg
Film-coated tablet; coated tablet; tablet.
On the market
- Earliest approval on file
- May 16, 2018 Lucemyra, Biocorrx Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 3 first August 20, 2024; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 7 of which 4 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $7.88 per tablet Lofexidine 0.18 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 161 through July 30, 2026
What is lofexidine used for?
From the label: indications and usageLUCEMYRA is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. LUCEMYRA is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Source: FDA drug label (LUCEMYRA), BioCorRx Pharmaceuticals Inc, effective July 22, 2026 (SPL set 0a848cc2-4dda-40d9-8b01-d789fe8981ed), via openFDA; the full label on DailyMed
What does the patient leaflet for lofexidine say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about LUCEMYRA and discontinuing opioid drugs?LUCEMYRA can cause serious side effects, including low blood pressure (hypotension), slow heart rate (bradycardia), and fainting. If you have any of the following signs or symptoms, tell your healthcare provider right away: low blood pressure lightheadedness slow heartbeat feeling faint at rest or when standing up dizziness If you take LUCEMYRA at home and have any of these signs and symptoms, do not take your next dose of LUCEMYRA until you have talked to your healthcare provider. You should avoid becoming dehydrated or overheated during treatment with LUCEMYRA, which may increase your risk of low blood pressure and fainting. You should also be careful not to stand up too suddenly from lying down or sitting. When your treatment is complete you will need to stop taking LUCEMYRA gradually or your blood pressure could increase. For more information about side effects, see “What are the possible side effects of LUCEMYRA?” Increased risk of opioid overdose. After a period of time of not using opioids drugs, you can become more sensitive to the effects of opioids if you start using opioids again. This may increase your risk of overdose and death.
From the patient leaflet: What should I avoid while taking LUCEMYRA?Do not drive, operate heavy machinery, or perform any other dangerous activities until you know how LUCEMYRA affects you.
From the patient leaflet: How should I store LUCEMYRA?Store LUCEMYRA at room temperature between 68°F to 77°F (20°C to 25°C). Keep LUCEMYRA in its original container. Keep LUCEMYRA away from heat and moisture. LUCEMYRA bottles contain desiccant packs to help keep the tablets dry. Do not remove the desiccant packs until all the tablets are used. Keep LUCEMYRA and all medicines out of the reach of children.
Source: FDA drug label (LUCEMYRA), BioCorRx Pharmaceuticals Inc, effective July 22, 2026 (SPL set 0a848cc2-4dda-40d9-8b01-d789fe8981ed), via openFDA; the full label on DailyMed
Is there a generic for lofexidine (Lucemyra)?
The FDA approved the first generic lofexidine on August 20, 2024. 3 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists lofexidine from 4 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2018 earliest approval on file
- 2024 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for lofexidine (Lucemyra)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $7.88 per Lofexidine 0.18 mg tablet, down 38% from $12.66 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Lofexidine 0.18 mg tablet (generic)
- Lucemyra 0.18 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Lofexidine 0.18 mg tablet | Generic | $7.88 per tablet | $236.38 | -38% |
| Lucemyra 0.18 mg tablet | Brand | $23.22 per tablet | $696.62 | no change |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the lofexidine label say about other medicines?
The lofexidine label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Methadone | drug interactions | DRUG INTERACTIONS Methadone: Methadone and LUCEMYRA both prolong the QT interval. |
| Naltrexone | drug interactions | ECG monitoring is recommended when used concomitantly. ( 7.1 ) Oral Naltrexone: Concomitant use may reduce efficacy of oral naltrexone. |
| Paroxetine | drug interactions | Concomitant use of paroxetine resulted in increased plasma levels of LUCEMYRA. |
Source: FDA drug label (LUCEMYRA), BioCorRx Pharmaceuticals Inc, effective July 22, 2026 (SPL set 0a848cc2-4dda-40d9-8b01-d789fe8981ed), via openFDA; the full label on DailyMed
What do FAERS reports show for lofexidine?
The FDA Adverse Event Reporting System holds 161 reports that list lofexidine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 24 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Lofexidine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other